Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis Review
| Authors: | Nocco, S.; Andriano, T. M.; Bose, A.; Chilov, M.; Godwin, K.; Dranitsaris, G.; Wu, S.; Lacouture, M. E.; Roeker, L. E.; Mato, A. R.; Markova, A. |
| Review Title: | Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis |
| Abstract: | The scope of dermatologic adverse events to ibrutinib has not been systematically described. We sought to determine the incidence and severity of ibrutinib-associated dermatologic toxicities and provide management recommendations. We conducted a systematic literature search of clinical trials and cohorts investigating ibrutinib monotherapy for cancer or chronic graft-versus-host disease through June 2020. Thirty-two studies with 2258 patients were included. The incidence of all-grade toxicities included cutaneous bleeds (24.8%; 95%CI, 18.6–31.0%), mucocutaneous infections (4.9%; 95%CI, 2.9–7.0%), rash (10.8%; 95%CI. 6.1–15.5%), mucositis (6%; 95%CI, 3.6–8.5%), edema (15.9%; 95%CI, 11.1–20.6%), pruritus (4.0%; 95%CI, 0.0–7.9%), xerosis (9.2%; 95%CI, 5.5–13.0%), nail changes (17.8%; 95%CI, 4.1–31.5%), and hair changes (7.9%; 95%CI, 0.0–21.3%). The incidence of high-grade toxicities included mucocutaneous infection (1.3%; 95%CI, 0.5–2.2%), rash (0.1%; 95%CI, 0.0–0.2%), mucositis (0.1%; 95%CI, 0.0–0.3%), and edema (0.1%; 95%CI, 0.0–0.2%). It is imperative that clinicians familiarize themselves with ibrutinib-associated dermatologic toxicities to learn how to manage them, prevent discontinuation, and improve patient outcomes. © 2022 Elsevier B.V. |
| Keywords: | cutaneous; toxicity; management; dermatology; kinase inhibitor; adverse event; bruton's tyrosine kinase; ibrutinib; dermatologic adverse events; btk inhibitor |
| Journal Title: | Critical Reviews in Oncology/Hematology |
| Volume: | 174 |
| ISSN: | 1040-8428 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2022-06-01 |
| Start Page: | 103696 |
| Language: | English |
| DOI: | 10.1016/j.critrevonc.2022.103696 |
| PUBMED: | 35523374 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 June 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work